Diabetes mellitus and tuberculosis treatment

Antituberculosis Chemotherapy

Volumn 10, Issue , 2011, Pages 203-212

  Ruslami, Rovina ^a   Van Crevel, Reinout ^b  

^a PADJADJARAN UNIVERSITY   (Indonesia)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925851525     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000324219     Document Type: Chapter

References (50)

1. Root HF: The association of diabetes and tuberculosis:epidemiology, pathology, treatment and prognosis. N Engl J Med 1934;210:1-13.
2. Boucot KR, Dillon ES, Cooper DA, Meier P, Richardson R: Tuberculosis among diabetics: the Philadelphia survey. Am Rev Tuberc 1952;65:1-50.
3. Luntz GR: Management of the tuberculosis diabetic:follow-up of 84 cases for one year. Br Med J 1957;i:1082-1086.
4. http://www.eatlas.idf.org/prevalence/index (accessed December 2, 2010).
5. World Health Organization: WHO Report 2010:Global Tuberculosis Control. WHO/HTM/TB/2010.7. Geneva, WHO, 2010.
6. Ruslami R, Aarnoutse RA, Alisjahbana B, van der Ven A, van Crevel R: Implications of global increase of diabetes for tuberculosis control and patient care. Trop Med Int Health 2010;15:1289-1299.
7. Jeon CY, Murray MB: Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008;5:e152.
8. Bloomgarden ZT: Inflammation and insulin resistance. Diabetes Care 2003;26:1922-1926.
9. Bacakoglu F, Basoglu OK, Cok G, Sayiner A, Ates M: Pulmonary tuberculosis in patients with diabetes mellitus. Respiration 2001;68:595-600.
10. Restrepo BI, Fisher-Hoch SP, Crespo JG, Whitney E, Perez A, Smith B, McCormick JB, Nuevo Santander Tuberculosis Trackers: Type 2 diabetes and tuberculosis in a dynamic bi-national border population. Epidemiol Infect 2007;135:483-491.
11. Weaver R: Unusual radiographic presentation of pulmonary tuberculosis in diabetic patients. Am Rev Respir Dis 1974;109:162-163.
12. Marais RM: Diabetes mellitus in black and colored tuberculosis patients. S Afr Med J 1980;57:483-484.
13. Hendy HH, Stableforth D: The effect of established diabetes mellitus on the presentation of infiltrative pulmonary tuberculosis in the immigrant Asian community of an inner city area of the United Kingdom. Br J Dis Chest 1983;77:87-90.
14. Ikezoe J, Takeuchi N, Johkoh T, Kohno N, Tomiyama N, Kozuka T, Noma K, Ueda T: CT appearance of pulmonary tuberculosis in diabetic and immunocompromised patients: comparison with patients who had no underlying disease. Am J Roentgenol 1992;159:1175-1179.
15. Morris JT, Seaworth BJ, McAllister CK: Pulmonary tuberculosis in diabetics. Chest 1992;102:539-541.
16. Umut S, Tosun GA, Yildirim N: Radiographic location of pulmonary tuberculosis in diabetic patients. Chest 1994;106:326.
17. Al-Wabel AH, Teklu B, Mahfouz AA, al-Ghamdi AS, el-Amin OB, Khan AS: Symptomatology and chest roentgenographic changes of pulmonary tuberculosis among diabetics. East Afr Med J 1997;74:62-64.
18. Perez-Guzman C, Torres-Cruz A, Villareal-Velarde H, Vargas MH: Progressive age-related changes in pulmonary tuberculosis images and the effect of diabetes. Am J Respir Crit Care Med 2000;162:1738-1780.
19. Perez-Guzman C, Torres-Cruz A Villareal-Velarde H, Salazar-Lezama MA, Vargas MH: Atypical radiological images of pulmonary tuberculosis in 192 diabetic patients: a comparative study. Int J Tuberc Lung Dis 2001;5:455-461.
20. Shaikh MA, Singla R, Khan NB, Sharif NS, Saigh MO: Does diabetes alter the radiological presentation of pulmonary tuberculosis? Saudi Med J 2003;24:278-281.
21. Nissapatorn V, Kuppusamy I, Jamaiah I, Fong MY, Rohela M, Anuar AK: Tuberculosis in diabetic patients: a clinical perspective. Southeast Asian J Trop Med Public Health 2005;36(suppl 4):213-220.
22. Wang JY, Lee LN, Hsueh PR: Factors changing the manifestation of pulmonary tuberculosis. Int J Tuberc Lung Dis 2005;9:777-783.
23. Wang CS, Chen HC, Yang CJ, Chen HC, Chuang SH, Chong IW, Hwang JJ, Huang MS: Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. Epidemiol Infect 2009;137:203-210.
24. Alisjahbana B, van Crevel R, Sahiratmadja E, den Heijer M, Maya A, Istriana E, Danusantoso H, Ottenhoff TH, Nelwan RH, van der Meer JW:Diabetes mellitus is strongly associated with tuberculosis in Indonesia. Int J Tuberc Lung Dis 2006;10:696-700.
25. Venkatesan K: Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 1992;22:47-65.
26. Zilly W, Breimer DD, Richter E: Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol 1975;9:219-227.
27. Syvälahti E, Pihlajamäki K, Iisalo E: Effect of tuberculostatic agents on the response of serum growth hormone and immunoreactive insulin to intravenous tolbutamide, and on the half-life of tolbutamide. Int J Clin Pharmacol Biopharm 1976;13:83-89.
28. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivisto KT: Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001;69:400-406.
29. Park JY, Kim KA, Park PW, Park CW, Shin JG:Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Clin Pharmacol Ther 2003;74:334-340.
30. Niemi M, Kivisto KT, Backman JT, Neuvonen PJ:Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. Br J Clin Pharmacol 2000;50:591-595.
31. Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivisto KT: Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2000;68:495-500.
32. Hatorp V, Hansen KT, Thomsen MS: Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 2003;43:649-660.
33. Bidstrup TB, Stilling N, Damkier P, Scharling B, Thomsen MS, Brosen K: Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol 2004;60:109-114.
34. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT: Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003;42:819-850.
35. Park JY, Kim KA, Kang MH, Kim SL, Shin JG:Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004;75:157-162.
36. Jaakkola T, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ: Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol 2006;61:70-78.
37. Nathan DM, Buse JB, Davidson M, Ferrannini E, Holman RR, Sherwin R, Zinman B: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;23:193-203.
38. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA: American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
39. Mitchison DA: Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000;4:796-806.
40. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff TH, Nelwan RH, Parwati I, van der Meer JW, van Crevel R: The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis 2007;45:428-435.
41. Wang CS, Chen HC, Yang CJ, Wang WY, Chong IW, Hwang JJ, Huang MS: The impact of age on the demographic, clinical, radiographic characteristics and treatment outcomes of pulmonary tuberculosis patients in Taiwan. Infection 2008;36:335-340.
42. Ridzon R, Whitney CG, McKenna MT, Taylor JP, Ashkar SH, Nitta AT, Harvey SM, Valway S, Woodley C, Cooksey R, Onorato IM: Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med 1998;157:1881-1884.
43. Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH, van der Ven AJ, Danusantoso H, Aarnoutse RE, van Crevel R: Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 2006;43:848-854.
44. Ruslami R, Nijland HM, Adhiarta IG, Kariadi SH, Alisjahbana B, Aarnoutse RE, van Crevel R: Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother 2010;54:1068-1074.
45. Burman WJ, Gallicano K, Peloquin C: Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet 2001;40:327-341.
46. Harries AD, Murray MB, Jeon CY, Ottmani SE, Lonnroth K, Barreto ML, Billo N, Brostrom R, Bygbjerg IC, Fisher-Hoch S, Mori T, Ramaiya K, Roglic G, Strandgaard H, Unwin N, Viswanathan V, Whiting D, Kapur A: Defining the research agenda to reduce the joint burden of disease from diabetes mellitus and tuberculosis. Trop Med Int Health 2010;15:659-663.
47. Pfaffenberg R, Jahler H: Isoniazid and recurrence of tuberculosis in diabetics. Z Tuberk 1958;111:167-173.
48. Lesnichii AV, Karpina LZ: Experience with the chemoprophylaxis of pulmonary tuberculosis in diabetes mellitus patients. Probl Tuberk 1969;47:1-3.
49. Ponce-de-Leon A, Garcia-Garcia ML, Garcia-Sancho MC, et al: Tuberculosis and diabetes in southern Mexico. Diabetes Care 2004;27:1584-1590.
50. Balde NM, Camara A, Camara LM, Diallo MM, Kake A, Bah-Sow OY: Associated tuberculosis and diabetes in Conakry, Guinea: prevalence and clinical characteristics. Int J Tuberc Lung Dis 2006;10:1036-1040.